CBLL1 Knockout HeLa Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal cell population derived from HeLa cervical adenocarcinoma epithelial cells, engineered to disrupt the CBLL1 gene. This loss-of-function model enables investigation of CBLL1-dependent regulation of cell-cell adhesion and epithelial-mesenchymal transition. The polyclonal format retains genetic variability, avoiding clonal bias while providing a robust platform for functional genomics.
HeLa cells are an HPV18-positive immortalized epithelial line originally derived from a cervical adenocarcinoma of a 31-year-old African-American woman. They serve as a widely used cancer model, particularly for studying cervical cancer progression, metastasis, and oncogenic signaling. Their well-characterized growth properties and signaling networks make them an exemplary host for gene-editing applications.
CBLL1 (HAKAI) functions as an E3 ubiquitin ligase that regulates epithelial integrity by targeting E-cadherin for proteasomal degradation. Activation of receptor tyrosine kinases, such as EGFR, triggers Src-mediated phosphorylation of E-cadherin, recruiting CBLL1 to the cadherin?Ccatenin complex. Subsequent ubiquitination promotes E-cadherin endocytosis and destruction, dismantling adherens junctions. This releases ??-catenin from the membrane, allowing its nuclear accumulation and transcriptional activation of mesenchymal genes. The pathway integrates signals from Src kinase and EGF, and involves core junctional components including p120-catenin and ??-catenin. Downstream, CBLL1 activity enhances cell migration, invasion, and epithelial-mesenchymal transition, linking it to metastatic dissemination.
In HeLa cells, disruption of CBLL1 is anticipated to stabilize E-cadherin at cell?Ccell contacts, strengthening adherens junctions and reducing the invasive capacity characteristic of this metastatic line. Coupled with the HPV18-positive background, where viral oncoproteins may intersect with ubiquitin-dependent pathways, this model offers a nuanced system for dissecting adhesion dynamics and EMT. The polyclonal knockout population maintains endogenous expression landscapes and cellular heterogeneity, making it suitable for physiologically relevant functional studies and drug response profiling.
Researchers can leverage CBLL1 Knockout HeLa Polyclonal Cells in diverse functional assays: western blotting and immunofluorescence to visualize E-cadherin stabilization at junctions; cell aggregation assays to quantify adhesion; transwell migration/invasion assays to assess metastatic potential and screen anti-metastatic compounds; in vitro ubiquitination assays to probe enzymatic regulation; and E-cadherin internalization assays to track trafficking dynamics. These applications support investigations into the ubiquitin-proteasome system, junctional plasticity, and EMT, with direct relevance to cancer biology and drug discovery. For further information, contact Ascent Research.
